Mounjaro Side Effects: From Nausea To Kidney Problems, Here Are All The Possible Harmful Effects

Quick Read
Summary is AI generated, newsroom reviewed.
Mounjaro (tirzepatide) is a weekly injectable drug for type-2 diabetes that aids weight loss by regulating appetite. Common side effects include nausea, diarrhea, and abdominal pain. Consult a doctor before use and monitor for potential interactions and side e
Mounjaro is a brand name for tirzepatide, a prescription drug primarily used to manage type-2 diabetes. This once-weekly injectable drug helps maintain healthy blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Recently, it has gained attention in the realm of weight management.
Mounjaro aids in weight loss by promoting feelings of fullness and reducing hunger, which contributes to a lower calorie intake. It is used widely by individuals who are overweight or obese, even those without diabetes, to shed weight more easily.
While there are benefits to using Mounjaro, it can also cause side effects. Below are some of the most common side effects reported:
Side effects of Mounjaro
As with any medication, Mounjaro can cause side effects. Some of the most common side effects reported include:
1. Nausea
This is the most frequently reported side effect and often decreases over time. Mounjaro slows down the emptying of the stomach which can cause nausea.
2. Diarrhea
Some individuals may experience gastrointestinal issues such as diarrhea, which can subside as the body adjusts.
3. Vomiting
Similar to nausea, vomiting can occur, especially when starting the medication.
4. Constipation
Due to changes in appetite and reduced intake of calories, Mounjaro can cause constipation. Adding more dietary fibre to the diet may help elevate this issue.
5. Abdominal pain
Discomfort in the stomach area is another potential side effect.
These symptoms often subside as the body gets used to it. Serious side effects, although rare, can include pancreatitis, gallbladder issues, kidney problems, allergic reactions and severe gastrointestinal issues.
It is crucial to seek medical attention immediately if you experience severe abdominal pain, changes in urination, or any signs of an allergic reaction.
Safety tips to follow
1. Consult a healthcare professional
Mounjaro is a prescription drug. Always speak to your doctor before starting Mounjaro. They can assess your medical history and determine if it's a suitable option for you.
2. Check blood sugar levels regularly
If you have diabetes, regularly checking your blood sugar levels is essential, especially when starting Mounjaro.
3. Start with low doses
Begin with a low dose to mitigate side effects and allow your body to adjust gradually. However, it is best to administer the dose prescribed by your doctor.
4. Follow a balanced diet
While Mounjaro can aid in weight loss, pairing it with a healthy, balanced diet can help keep digestion healthy.
5. Stay hydrated
Due to potential gastrointestinal effects, ensure you drink plenty of fluids to stay hydrated.
6. Be aware of potential interactions
Check with your doctor if you are currently taking any medication to avoid any potential interactions.
Keep track of any side effects you experience and attend regular check-ups with your doctor. It is advisable to undergo regular kidney function tests, liver function panels, and monitor for any abdominal symptoms while using this medication.
Mounjaro is generally considered safe for use under medical supervision, especially for individuals who are overweight or obese. While it offers substantial benefits, understanding potential side effects and adhering to safety measures is crucial.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

13 hours ago

• Mint

How weight-loss drugs blew out the US trade deficit

Planes have been jetting from Ireland to the U.S. this year carrying something more valuable than gold: $36 billion worth of hormones for popular obesity and diabetes drugs. The frantic airlift of those ingredients—more than double what was imported from Ireland for all of last year—reflects the collision of two powerful forces: tariff-driven stockpiling and weight-loss drug demand. The peptide and protein-based hormones feed into a category of drugs that include wildly popular GLP-1 treatments and newer types of insulin known as analogues. Taken together the shipments weighed just 23,400 pounds, according to U.S. trade data, equivalent to the weight of less than four Tesla Cybertrucks. Fit into temperature-controlled air cargo containers, the pharmaceutical ingredients have had a huge impact on the U.S. trade imbalance. The shipments have vaulted Ireland, a country of only 5.4 million people, into the second-largest goods-trade imbalance with the U.S., trailing only China. They accounted for roughly half of the $71 billion in goods the U.S. imported from the country in the first four months of the year. Nearly 100% of the imports had a final destination of Indiana, according to U.S. customs records. Eli Lilly, the drug giant behind weight loss and diabetes drugs Zepbound and Mounjaro, is headquartered in Indianapolis. A Lilly spokeswoman declined to comment. President Trump's off-and-on trade war has rewritten global trading patterns this year and—temporarily, at least—widened some of the imbalances he is seeking to eliminate. Companies have scrambled to get shipments to the U.S. ahead of tariff deadlines, with a first round of front-loading ahead of the April 2 announcement, and smaller pushes after the White House paused some of its tariffs. Ireland is at the epicenter of the global rush. It is a major hub for U.S. drug giants, who have been expanding operations there in part because of Ireland's favorable tax policies. Some of the bestselling drugs in the world, such as AbbVie's anti-wrinkle treatment Botox, and U.S. drugmaker Merck's cancer treatment Keytruda, are made in the country. 'It's common sense. It's uncertain at the moment, so you're building a bit of security by stockpiling," said Matt Moran, a consultant and former director of industry group BioPharmaChem Ireland. 'There's such huge demand for those products at the moment." The trade imbalance has put Ireland into an uncomfortable position, landing it earlier this month on the U.S. Treasury Department's monitoring list for currency manipulation, which the government uses to send a warning shot to countries it thinks use unfair trade practices. Ireland's central bank said in a report Thursday that new factories making weight-loss drug ingredients helped drive the country's exports. Ireland's first-quarter economic growth expanded by nearly 10% in the first quarter thanks to the export surge. The attention is 'definitely not welcome," said Dan O'Brien, chief economist of the Institute of International and European Affairs, a Dublin think tank. 'A very big part of the U.S.-EU deficit is accounted for by Ireland alone. Trump doesn't like deficits." The White House wants American drug companies to bring production home and in April ordered a so-called Section 232 investigation that could result in tariffs on both imported drugs and ingredients like hormones. Trump said this week that such tariffs could come 'very soon." Lilly is a force in the market for weight-loss drugs, with sales of its GLP-1 medicines Mounjaro and Zepbound expected to nearly double this year to about $30 billion, according to Bank of America analysts. Maintaining supply of weight-loss drugs has been a challenge for both Lilly and rival Novo Nordisk, the Danish maker of Ozempic and Wegovy. The companies were initially unable to keep up with demand for the drugs. Lilly resolved the shortages faster, helping it to take market share from Novo. Lilly is now preparing for the potential launch of a weight-loss pill, orforglipron, which it plans to submit for U.S. approval later this year. Lilly said it began producing weight-loss and diabetes medicines at its Irish factory in Kinsale in 2023. Novo doesn't produce weight-loss drugs in Ireland, according to a spokeswoman. Peptide and protein-based hormones help to regulate processes such as appetite and metabolism. The category includes hormones that mimic a naturally occurring gut hormone called glucagon-like peptide-1, or GLP-1, but can also be used in some fertility and osteoporosis treatments. Shipping and logistics companies say they have noticed increased demand for pharma shipments, which often travel by air instead of on cheaper ocean freighters because they are so light and valuable. Pharma shipments more than doubled from Ireland to the U.S. in March and April, according to data firm WorldACD. Kuehne + Nagel, a Swiss logistics company with operations in the country, said its teams did overtime to accommodate the increase in booking requests and the customs paperwork. 'We didn't see the same increase from Ireland to the rest of the world. That was not a global trend," said Nico Sacco, the company's senior vice president of healthcare strategy. Imports of vaccines and various other drugs including cancer treatments also increased this year from Ireland, according to trade data. Merck produces cancer treatment Keytruda, the world's bestselling drug, in Ireland, among other places. Merck Chief Executive Rob Davis in April said the company has enough supply to mitigate any impact this year from tariffs and is working on navigating the long-term fallout of tariffs. Merck recently began construction on its first U.S. plant to make Keytruda. Lilly said earlier this year it plans to invest $27 billion in expanding U.S. production. The hormones are often freeze dried and shipped as powders. Obesity-related drugs can fly in the cargo sections of passenger planes, or on cargo flights reserved for pharma products, said Anand Kulkarni, head of global markets at Lufthansa Cargo. Lufthansa saw demand for U.S.-bound pharma shipments from locations such as India, Switzerland and Belgium. Volumes began to dip in April as warehouses in the U.S. reached capacity, he said. To increase shipments, drug companies likely tapped existing stocks and diverted production destined for the rest of the world to the U.S. market instead, industry executives said. 'You can't just switch on capacity. You don't go out and buy machines and start them up," said Moran, the consultant. 'They have to be built, commissioned, validated, and approved by the regulator." Write to Chelsey Dulaney at and Jared S. Hopkins at

Business Standard

15 hours ago

• Business Standard

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The US-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May, according to data from research firm PharmaTrac. With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the US. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24 per cent of women and nearly 23 per cent of men aged 15 to 49 were overweight or obese, up from 20.6 per cent and 19 per cent, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Time of India

17 hours ago

• Time of India

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: 1 simple trick to get all TV channels Techno Mag Learn More Undo With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the U.S. Live Events "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19%, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India.